mProX™ Human LAIR1 Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;Caki-2

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

Cancer Research

Related Diseases

Malaria

Gene ID

Human:3903

UniProt ID

Human:Q6GTX8

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

LAIR1, or leukocyte-associated immunoglobulin-like receptor-1, has been studied in various contexts. In osteosarcoma, LAIR1 has been found to be involved in influencing prognosis and the immune microenvironment. It has also been identified as a driver of glioma progression, promoting the expression of cyclin D1 and immunosuppressive chemokines/cytokines. In hepatocellular carcinoma, LAIR1 has been linked to oxidative stress response and identified as a predictor of early occurrence and prognosis. Additionally, LAIR1 has been studied in the context of macrophage effector function, where it was found to regulate antibody-dependent cellular phagocytosis. In gliomas, FCGR2B, a gene related to LAIR1, has been identified as a prognostic marker and immune microenvironmental marker. These findings provide insights into the role of LAIR1 and related genes in cancer progression and immune response.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human LAIR1 Stable Cell Line (S01YF-1023-PY276). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Morgan Brown (Verified Customer)

How does LAIR1 contribute to tumor immune suppression? Jan 29 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

LAIR1 expression leads to increased CD8+ T cell exhaustion and generates resistance to PD-1/PD-L1 immunotherapy in cancer, mediated by collagen in the tumor microenvironment. Jan 29 2022

chat Alex Williams (Verified Customer)

Can targeting LAIR1 enhance cancer immunotherapy? Jul 18 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

Blocking LAIR1 signaling in immune cells inhibits tumor development and metastasis, suggesting that targeting LAIR1 can enhance the efficacy of cancer immunotherapy. Jul 18 2023

Published Data

Fig.1 Anchorage-dependent cell proliferation was inhibited in Caki-2 cells through the suppression of LAIR1 knockdown.

In anchorage-dependent cell proliferation assays, an examination was conducted on Caki-2 cells that had been transfected with LAIR1 siRNA. The results presented here represent the mean ± SD of three independent experiments, with statistical significance observed as ***P<0.001 and ****P<0.0001 when compared to NC siRNA, as determined by one-way ANOVA.

Ref: Jingushi, Kentaro, et al. "Leukocyte‑associated immunoglobulin‑like receptor 1 promotes tumorigenesis in RCC." Oncology Reports 41.2 (2019): 1293-1303.

Pubmed: 30483814

DOI: 10.3892/or.2018.6875

Research Highlights

Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
The study aimed to examine the impact of ferroptosis-related long non-coding RNAs (FRLncs) on the prognosis and immune microenvironment of osteosarcoma (OS). This research sought to establish a foundational framework to aid in clinical decision making for OS management. The results of this investigation may provide valuable insights into the potential role of FRLncs in influencing the progression of OS and may have implications for future treatment strategies.
Yang, Mingyi. et al. "Ferroptosis-related lncRNAs guiding osteosarcoma prognosis and immune microenvironment." Journal of orthopaedic surgery and research, 2023.
Pubmed: 37858131 DOI: 10.1186/s13018-023-04286-3

Wei, Xiaoqian. et al. "LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines." Cell death & disease, 2023.
The immune receptor Leukocyte-associated immunoglobulin-like receptor-1 (LAIR1) containing immunoreceptor tyrosine-based inhibitory motifs (ITIMs) is being studied as a potential target for cancer therapy. However, its role in gliomas is still not fully understood. In this research, the correlation between LAIR1 and poor prognosis of glioma patients, as well as the aggressive growth of glioma cells, was investigated. It was discovered that LAIR1 promotes the nuclear localization of focal adhesion kinase (FAK), leading to increased expression of cyclin D1 and chemokines/cytokines (CCL5, TGFŒ≤2, and IL33). Furthermore, LAIR1 was found to be involved in the immunosuppressive glioma microenvironment by facilitating CCL5-mediated polarization of microglia/macrophages. The role of SHP2 in this process was also explored.
Wei, Xiaoqian. et al. "LAIR1 drives glioma progression by nuclear focal adhesion kinase dependent expressions of cyclin D1 and immunosuppressive chemokines/cytokines." Cell death & disease, 2023.
Pubmed: 37845206 DOI: 10.1038/s41419-023-06199-9